Idiopathic Nephrotic Syndrome clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 2-25
This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
San Francisco, California and other locations